The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Continuous Manufacturing (CM) of biologics has been a hot topic for recent years because it has a potential for improving the efficiency, agility, and flexibility of drug substance and drug product manufacturing. In addition, ICH Q13 reached to step 2 on July 27, and is expected to progress to step 4 next year. This session will discuss ICH Q13 updates and perspectives from regulators and industry for CM of biologics.